Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
NICE sits at the center of two critical enterprise markets: customer experience and financial crime prevention. This piece breaks down what is changing inside the business and why its next phase of cloud and AI adoption matters for investors.
Over the past six months, Hologic has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $74.17, representing a healthy 31.3% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date rallies.
Medical technology company Hologic (NASDAQ:HOLX) announced better-than-expected revenue in Q3 CY2025, with sales up 6.2% year on year to $1.05 billion. Its non-GAAP profit of $1.13 per share was 2.7% above analysts’ consensus estimates.
